- Home
- JVA vs OTLK Comparison
JVA vs OTLK Comparison
Compare JVA & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JVA
- OTLK
- Stock Information
- Founded
- JVA 1971
- OTLK 2010
- Country
- JVA United States
- OTLK United States
- Employees
- JVA N/A
- OTLK N/A
- Industry
- JVA Packaged Foods
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JVA Consumer Staples
- OTLK Health Care
- Exchange
- JVA Nasdaq
- OTLK Nasdaq
- Market Cap
- JVA 47.3M
- OTLK 56.3M
- IPO Year
- JVA 2005
- OTLK 2016
- Fundamental
- Price
- JVA $3.63
- OTLK $1.21
- Analyst Decision
- JVA
- OTLK Strong Buy
- Analyst Count
- JVA 0
- OTLK 5
- Target Price
- JVA N/A
- OTLK $10.20
- AVG Volume (30 Days)
- JVA 383.0K
- OTLK 358.2K
- Earning Date
- JVA 03-21-2025
- OTLK 05-14-2025
- Dividend Yield
- JVA N/A
- OTLK N/A
- EPS Growth
- JVA 6252.13
- OTLK N/A
- EPS
- JVA 0.53
- OTLK N/A
- Revenue
- JVA $80,327,181.00
- OTLK N/A
- Revenue This Year
- JVA N/A
- OTLK N/A
- Revenue Next Year
- JVA N/A
- OTLK $288.46
- P/E Ratio
- JVA $7.31
- OTLK N/A
- Revenue Growth
- JVA 15.77
- OTLK N/A
- 52 Week Low
- JVA $1.23
- OTLK $0.87
- 52 Week High
- JVA $9.93
- OTLK $9.98
- Technical
- Relative Strength Index (RSI)
- JVA 39.02
- OTLK 34.51
- Support Level
- JVA $3.10
- OTLK $1.15
- Resistance Level
- JVA $4.05
- OTLK $1.31
- Average True Range (ATR)
- JVA 0.54
- OTLK 0.12
- MACD
- JVA -0.12
- OTLK -0.01
- Stochastic Oscillator
- JVA 22.18
- OTLK 15.29
About JVA Coffee Holding Co. Inc.
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.